MorphoSys is a biotechnology company focused on developing innovative therapies. They have conducted research on MOR202 in combination with low-dose dexamethasone and continue to fund and support clinical evaluations of their therapies as of 2026.

MorphoSys is a biotechnology company focused on developing innovative therapies. They have conducted research on MOR202 in combination with low-dose dexamethasone and continue to fund and support clinical evaluations of their therapies as of 2026.